Shares of DexCom Inc. slipped 3.69% to $69.47 Thursday, on what proved to be an all-around poor trading session for the stock ...
A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...
The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...
Zacks Investment Research on MSN1d
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 ApprovalDexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the ...
Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former Masimo exec Jon Coleman joined Dexcom, and Sibionics’ CGM earned the CE mark.
Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...
The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...
Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...
StockStory.org on MSN4d
DexCom (DXCM): 3 Reasons We Love This StockDexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 8% to $74.17 per share. This run-up ...
DexCom (DXCM) announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for ...
Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last ...
DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback